Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer

G A M Govaert; R.J. Oostenbroek; P.W. Plaisier

doi:10.1016/j.ejso.2004.12.009

Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer

G A M Govaert, R.J. Oostenbroek, P.W. Plaisier

Department of Traumatology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIMS: To investigate the duration of staining of the skin after intradermal injection of patent blue during sentinel lymph node biopsy (SLNB) for breast cancer.

METHODS: The clinical data of 33 consecutive patients who underwent a SLNB in combination with breast conserving therapy (BCT) in our hospital were retrospectively reviewed. Also, patients were interviewed at intervals of 3 months until the blue staining of their skin had disappeared.

RESULTS: At mean follow-up of 18 months (range: 12-28) patent blue was visible at the site of injection after 3, 6, 9 and 12 months in 70, 64, 44 and 41% of the patients, respectively.

CONCLUSIONS: Use of the intradermal injection technique of patent blue during sentinel lymph node biopsy in BCT may result in remarkably long discolouring of the skin at the site of injection.

Original language	English
Pages (from-to)	373-5
Number of pages	3
Journal	European Journal of Surgical Oncology
Volume	31
Issue number	4
DOIs	https://doi.org/10.1016/j.ejso.2004.12.009
Publication status	Published - 2005

Keywords

Breast Neoplasms
Female
Follow-Up Studies
Humans
Injections, Intradermal
Retrospective Studies
Rosaniline Dyes
Sentinel Lymph Node Biopsy
Skin
Staining and Labeling
Time Factors
Journal Article

Access to Document

10.1016/j.ejso.2004.12.009

Cite this

@article{affc00a7f3d74fa7851c0b50846b53b8,

title = "Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer",

abstract = "AIMS: To investigate the duration of staining of the skin after intradermal injection of patent blue during sentinel lymph node biopsy (SLNB) for breast cancer.METHODS: The clinical data of 33 consecutive patients who underwent a SLNB in combination with breast conserving therapy (BCT) in our hospital were retrospectively reviewed. Also, patients were interviewed at intervals of 3 months until the blue staining of their skin had disappeared.RESULTS: At mean follow-up of 18 months (range: 12-28) patent blue was visible at the site of injection after 3, 6, 9 and 12 months in 70, 64, 44 and 41% of the patients, respectively.CONCLUSIONS: Use of the intradermal injection technique of patent blue during sentinel lymph node biopsy in BCT may result in remarkably long discolouring of the skin at the site of injection.",

keywords = "Breast Neoplasms, Female, Follow-Up Studies, Humans, Injections, Intradermal, Retrospective Studies, Rosaniline Dyes, Sentinel Lymph Node Biopsy, Skin, Staining and Labeling, Time Factors, Journal Article",

author = "Govaert, {G A M} and R.J. Oostenbroek and P.W. Plaisier",

year = "2005",

doi = "10.1016/j.ejso.2004.12.009",

language = "English",

volume = "31",

pages = "373--5",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer

AU - Govaert, G A M

AU - Oostenbroek, R.J.

AU - Plaisier, P.W.

PY - 2005

Y1 - 2005

N2 - AIMS: To investigate the duration of staining of the skin after intradermal injection of patent blue during sentinel lymph node biopsy (SLNB) for breast cancer.METHODS: The clinical data of 33 consecutive patients who underwent a SLNB in combination with breast conserving therapy (BCT) in our hospital were retrospectively reviewed. Also, patients were interviewed at intervals of 3 months until the blue staining of their skin had disappeared.RESULTS: At mean follow-up of 18 months (range: 12-28) patent blue was visible at the site of injection after 3, 6, 9 and 12 months in 70, 64, 44 and 41% of the patients, respectively.CONCLUSIONS: Use of the intradermal injection technique of patent blue during sentinel lymph node biopsy in BCT may result in remarkably long discolouring of the skin at the site of injection.

AB - AIMS: To investigate the duration of staining of the skin after intradermal injection of patent blue during sentinel lymph node biopsy (SLNB) for breast cancer.METHODS: The clinical data of 33 consecutive patients who underwent a SLNB in combination with breast conserving therapy (BCT) in our hospital were retrospectively reviewed. Also, patients were interviewed at intervals of 3 months until the blue staining of their skin had disappeared.RESULTS: At mean follow-up of 18 months (range: 12-28) patent blue was visible at the site of injection after 3, 6, 9 and 12 months in 70, 64, 44 and 41% of the patients, respectively.CONCLUSIONS: Use of the intradermal injection technique of patent blue during sentinel lymph node biopsy in BCT may result in remarkably long discolouring of the skin at the site of injection.

KW - Breast Neoplasms

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Injections, Intradermal

KW - Retrospective Studies

KW - Rosaniline Dyes

KW - Sentinel Lymph Node Biopsy

KW - Skin

KW - Staining and Labeling

KW - Time Factors

KW - Journal Article

U2 - 10.1016/j.ejso.2004.12.009

DO - 10.1016/j.ejso.2004.12.009

M3 - Article

C2 - 15837042

SN - 0748-7983

VL - 31

SP - 373

EP - 375

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

IS - 4

ER -

Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this